A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

L. Mayer, Erica; Baurain, Jean‐François; A. Sparano, Joseph; C. Strauss, Lewis; Campone, Mario; Fumoleau, P.; S. Rugo, Hope; Awada, Ahmad; Sy, Oumar; Llombart‐Cussac, Antonio

doi:10.1158/1078-0432.ccr-11-0070

Public

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Published in Clinical Cancer Research • Sep 9, 2011

Authors:

Erica L. Mayer

Jean‐François Baurain

Joseph A. Sparano

Abstract

PURPOSE: SRC-family kinases (SFK) are involved in numerous oncogenic signaling pathways. A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive (HR+) ad...

Subject

Dasatinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!